The Effectiveness and Value of Esketamine for the Management of Treatment-Resistant Depression

J Manag Care Spec Pharm. 2020 Jan;26(1):16-20. doi: 10.18553/jmcp.2020.26.1.16.


Funding for this summary was contributed by the Laura and John Arnold Foundation, National Institute for Health Care Management, California Health Care Foundation, Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Healthcare, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from Aetna, America's Health Insurance Plans, Anthem, AstraZeneca, Allergan, Alnylam, Biogen, Blue Shield of California, Cambia Health Services, CVS Caremark, Editas, Express Scripts, Genentech, GlaxoSmithKline, Harvard Pilgrim Health Care, Health Care Service Corporation, HealthPartners, HealthFirst, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinkrodt Pharmaceuticals, Merck, Novartis, National Pharmaceutical Council, Premera, Prime Therapeutics, Regeneron, Sanofi, Spark Therapeutics, and United Healthcare. Agboola, Fazioli, and Pearson are employed by ICER. Touchette reports grants from ICER during the course of this work and personal fees from Monument Analytics, unrelated to this work. Atlas has nothing to disclose.

Publication types

  • Congress

MeSH terms

  • Administration, Intranasal
  • Adolescent
  • Adult
  • Aerosols
  • Affect / drug effects*
  • Aged
  • Antidepressive Agents / administration & dosage*
  • Antidepressive Agents / adverse effects
  • Antidepressive Agents / economics*
  • Comparative Effectiveness Research
  • Cost-Benefit Analysis
  • Depressive Disorder, Treatment-Resistant / diagnosis
  • Depressive Disorder, Treatment-Resistant / drug therapy*
  • Depressive Disorder, Treatment-Resistant / economics*
  • Depressive Disorder, Treatment-Resistant / psychology
  • Drug Costs*
  • Evidence-Based Medicine
  • Female
  • Humans
  • Ketamine / administration & dosage*
  • Ketamine / adverse effects
  • Ketamine / economics*
  • Male
  • Middle Aged
  • Patient Safety
  • Policy Making
  • Randomized Controlled Trials as Topic
  • Treatment Outcome
  • Young Adult


  • Aerosols
  • Antidepressive Agents
  • Esketamine
  • Ketamine